All Pathways
NeurologyManagement

Chronic Epilepsy Management

Chronic Epilepsy Management: Epilepsy Diagnosis Confirmed → Classify Seizure Type → Assess Patient Factors → Seizure Type? → Focal Seizure AEDs.

Interactive Decision Tree

Mini Map

Algorithm Steps

  1. Start

    Epilepsy Diagnosis Confirmed

    ≥2 unprovoked seizures or 1 seizure with high recurrence risk

    1. Action

      Classify Seizure Type

      ILAE 2017 Classification

      • Focal onset (aware vs impaired awareness)
      • Generalized onset (tonic-clonic, absence, etc.)
      • Unknown onset
      • Determines AED choice
      1. Action

        Assess Patient Factors

        Influences AED selection

        • Age and sex
        • Childbearing potential (teratogenicity)
        • Comorbidities (mood, migraine, weight)
        • Drug interactions
        • Cost and access
        1. Decision

          Seizure Type?

          Focal vs Generalized

          1. Action

            Focal Seizure AEDs

            First-line options

            • Levetiracetam (broad, few interactions)
            • Lamotrigine (good for women, slow titration)
            • Oxcarbazepine (better tolerated than CBZ)
            • Carbamazepine (older, effective)
            • Lacosamide (newer, well-tolerated)
            1. Warning

              ⚠️ Women of Childbearing Potential

              Avoid valproate

              • Valproate: highest teratogenicity risk
              • Prefer: lamotrigine, levetiracetam
              • Folic acid 0.4-4 mg daily
              • Preconception counseling essential
              • Plan pregnancies
              1. Action

                Start Selected AED

                Monotherapy first

                • Start low, titrate slowly
                • Target lowest effective dose
                • Allow 2-3 months for steady state
                • Check levels if available (PHT, VPA, CBZ)
                1. Decision

                  Seizure Freedom at 2-3 Months?

                  Adequate response?

                  1. Action

                    Continue Current Therapy

                    Maintenance phase

                    • Regular follow-up (q3-6 months)
                    • Monitor for side effects
                    • Assess adherence
                    • Discuss driving restrictions
                    1. Action

                      Consider AED Withdrawal

                      If seizure-free ≥2 years

                      • Discuss risks/benefits
                      • Recurrence risk ~30-40%
                      • Lower risk: normal EEG, no structural lesion
                      • Higher risk: focal onset, abnormal EEG
                      • Taper slowly over months
                      1. Outcome

                        Long-Term Management

                        Ongoing care and monitoring

                  2. Action

                    Adjust Therapy

                    If breakthrough seizures

                    • Check adherence first
                    • Increase dose if tolerated
                    • Check drug levels
                    • Review for triggers (sleep, alcohol)
                    1. Decision

                      Still Uncontrolled?

                      Switch or add second AED

                      • Trial of 2-3 AEDs defines drug-resistant
                      • Switch: if first AED not tolerated
                      • Add-on: if partial response
                      1. Warning

                        Drug-Resistant Epilepsy

                        Failed 2 appropriate AEDs

                        • Refer to epilepsy center
                        • Consider surgery evaluation
                        • VNS, RNS options
                        • Dietary therapy (ketogenic)
                        • ~30% of epilepsy is drug-resistant
          2. Action

            Generalized Seizure AEDs

            Broad-spectrum preferred

            • Levetiracetam (first-line, broad)
            • Valproate (very effective, teratogenic)
            • Lamotrigine (good for women)
            • Avoid: CBZ, OXC, PHT (can worsen absence)
            • Ethosuximide for absence only

Guideline Source

AAN/AES Practice Parameter: Treatment of New-Onset and Chronic Epilepsy

Clinical Safety Information

Clinical Decision Support — Not a Substitute for Clinical Judgment

Individual patient factors may require deviation from these recommendations.

Known Limitations

  • Pediatric epilepsy has different considerations
  • Drug interactions complex - check always
  • Pregnancy requires specialized management
  • Status epilepticus covered separately

Applicable Regions

USEUglobal

EU: ILAE guidelines similar

US: AAN/AES 2018 guidelines, reaffirmed 2024

Version 1Next review: 2027-01-01

Frequently Asked Questions

What is the Chronic Epilepsy Management?

The Chronic Epilepsy Management is a management clinical algorithm for Neurology. It provides a structured decision tree to guide clinical decision-making, based on AAN/AES Practice Parameter: Treatment of New-Onset and Chronic Epilepsy.

What guideline is the Chronic Epilepsy Management based on?

This algorithm is based on AAN/AES Practice Parameter: Treatment of New-Onset and Chronic Epilepsy (DOI: 10.1212/WNL.0000000000005940).

What are the limitations of the Chronic Epilepsy Management?

Known limitations include: Pediatric epilepsy has different considerations; Drug interactions complex - check always; Pregnancy requires specialized management; Status epilepticus covered separately. Individual patient factors may require deviation from these recommendations.

Get AI-Powered Analysis Alongside This Algorithm

In AttendMe.ai, the Chronic Epilepsy Management appears automatically when your clinical question matches — alongside evidence from 3M+ peer-reviewed articles.

Try AttendMe Free